Výsledky vyhledávání - "Matthew Robert Warr"

Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite—Resolution for Clinical Development

Autor: Jim Zheng, Matthew Robert Warr, Bill J. Smith, Lisa Moorehead, Bernard P. Murray, Jeffrey A. Silverman, John Ling, Raju Subramanian, Jingyu Zhang, Yan Xin, Ellen Kwan, J. Andrew Whitney, Hemenway Jeffrey N

Publikováno v: Drug Metabolism and Disposition. 46:237-247

Momelotinib (MMB), a small-molecule inhibitor of Janus kinase (JAK)1/2 and of activin A receptor type 1 (ACVR1), is in clinical development for the treatment of myeloproliferative neoplasms. The pharmacokinetics and disposition of [14C]MMB were chara

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6ca91bf722b61fe9a2e7b79eeb79385
https://doi.org/10.1124/dmd.117.078899

Zobrazit plný text záznamu

Preclinical Modeling of ACVR1-Dependent Hepcidin Production and Anemia By Momelotinib

Autor: Igor Theurl, Matthew Robert Warr, Malte Asshoff, Guenter Weiss, Shringi Sharma, Pat Maciejewski, J. Andrew Whitney, Jim Zheng

Publikováno v: Blood. 128:1967-1967

Patients with myelofibrosis (MF) often develop anemia and frequently become dependent on red blood cell transfusions. Elevated levels of hepcidin in MF patients suggest that deregulated iron homeostasis is a driver of anemia in MF (Pardanani et al.,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::696a2038d95d05f7c8fd0bb9df3e1f2e
https://doi.org/10.1182/blood.v128.22.1967.1967

Zobrazit plný text záznamu

The Jak1/Jak2 Inhibitor Momelotinib Inhibits Alk2, Decreases Hepcidin Production and Ameliorates Anemia of Chronic Disease (ACD) in Rodents

Autor: Andy Whitney, Verena Petzer, Manfred Nairz, Igor Theurl, Pat Maciejewski, Piotr Tymoszuk, David Haschka, Egon Demetz, Markus Seifert, Malte Asshoff, Matthew Robert Warr, Peter Fowles, Guenter Weiss, Wilfried Posch

Publikováno v: Blood. 126:538-538

Many patients with myelofibrosis (MF) develop anemia and are, or become, dependent on frequent red blood cell transfusions [1]. Results from the phase 2 studies for the treatment of myelofibrosis (MF) with the Jak1/2 inhibitor momelotinib (MMB) demon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8bd02c01f9f93a9cc553aa27733c49f6
https://doi.org/10.1182/blood.v126.23.538.538

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání